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CHAPTER 1 
M.A.M. van Boekel 
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GENERAL INTRODUCTION 
Diabetes is one of the most common diseases in the world. In the Netherlands 
about 2% of the population is suffering from diabetes mellitus. It can be divided 
into juvenile diabetes (insulin-dependent diabetes mellitus, IDDM, or type I 
diabetes) and maturity-onset diabetes (non-insulin dependent diabetes mellitus, 
NIDDM or type II). Due to insufficient insulin production, blood sugar levels in 
patients are elevated dramatically. Possibly, these high levels are responsible for the 
occurrence of the wide range of complications accompanying diabetes. Reducing 
sugars have shown to react easily with protein residues in a process called non-
enzymatic glycosylation or glycation. There is evidence that the same mechanism 
plays a role in aging in normal healthy individuals: the most dramatic age-related 
changes involve tissues which contain long-lived proteins such as the eye lens. 
Furthermore, age-related processes are accelerated in diabetics, whereas food 
restriction, resulting in low blood sugar levels, retards these age-related processes. 
These observations can be explained by a common mechanism based on the initial 
reaction of reducing sugars with free amino groups of proteins. 
OUTLINE OF THIS THESIS 
It is now clear that the Maillard reaction, though originally only thought to occur in 
vitro, takes place at a large scale in vivo, especially in long-lived proteins. The 
crystallins are a very suitable object for the investigation of age-related changes such 
as glycation. The lens grows during the life of the individual by building up cells 
layer after layer around a central core. As a result, proteins in the center of the 
lens are as old as the individuals themselves, while crystallins in the outer cortex are 
only just synthesized. 
Initial experiments were done in vitro, using calf lens crystallins as a model, to 
investigate the changes caused by a number of reducing sugars. This included both, 
so-called early and advanced glycation products of the browning reaction (chapter 
2). 
In the work discussed in chapter 3, we investigated the in vivo glycation of bovine 
crystallins. To elucidate the influence of aging, we used lenses of different age. 
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Levels of both, early as well as advanced glycation products, were determined in the 
various crystallin fractions. We also compared the extent of glycation of aA- versus 
aB-subunits. 
Human lenses were used for the experiments described in chapter 4. As we wanted 
to focus our attention on the influence of glycation on both, aging and diabetes, we 
used clear lenses of different age, and lenses from individuals showing senile or 
diabetic cataract. Glycation levels of high-molecular-weight material, α-, β- and 7 -
crystallins were determined. 
Though the glycation of albumin and hemoglobin is extensively investigated, 
modification of immunoglobulins is not well described. The work discussed in 
chapter 5 deals with in vitro and in vivo glycation of immunoglobulins G, A and M 
in diabetics and normal healthy individuals. 
Much effort has been spent at finding suitable non-toxic inhibitors of the Maillard 
reaction. Well described examples are acetylsalicylic acid (Aspirin) and glutathion. 
Recent experiments show the inhibitory effect of Ibuprofen and paracetamol on the 
glycation of serum proteins. Chapter 6 adds the effects of another anti-inflammatory 
drug, diclofenac, on the glycation of human serum albumin. 
THE ROLE OF GLYCATION IN AGING AND DIABETES MELLITUS 
ABSTRACT 
One of the hypotheses trying to explain the process of aging is the idea of gfycation of 
proteins. This reaction, also called the Maillard or browning reaction, may explain age-
related symptoms such as cataract, atherosclerosL· and modification of collagen-
containing tissues. Diabetics, which posses elevated blood sugar levels, show signs of 
accelerated aging exposing similar complications. The Maillard reaction, which occurs 
on a large scale in vivo, may play a key role in the initiation of these symptoms. 
INTRODUCTION 
Glycation is a reaction between sugars and proteins which takes place without the 
aid of enzymes. The reaction was first described by Louis Maillard [1], who 
observed the browning of protein samples upon heating with sugars. For many 
years, the "Maillard reaction" seemed only important for food chemistry. Not until 
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1975 discoveries where made which revealed the relevance of glycation in vivo. 
Glycation seems to occur in every living organism. It is especially important in 
individuals with elevated blood-sugar levels such as patients with diabetes mellitus 
and galactosemia. Proteins with a long half-life are more intensely subjected to this 
modification process. 
Recent research has made clear that glycation in vivo has serious consequences for 
the biological functions of proteins. Thus, glycation seems to play a role in both, 
aging and the pathological complications of patients with diabetes mellitus. 
Chemistry 
The first step in the glycation process is the reaction between the aldehyde group of 
a reducing sugar and the free amino group of a protein (this can be the terminal 
amino group or the e-aminogroup of lysine). The result is a still labile Schiff base, 
which undergoes a rearrangement to form the more stable Amadori product. 
H H 
I I i 
R , — C H O H — C = 0 + NH2—R2 ^ R,—CHOH—C=N—R 2 ï± R,—CO—CH 2 —NH—R 2 - . - . -.AGE's 
sugar protein Schiff base Amadori product 
The Schiff base and Amadori product are called the early glycation products. The 
sugar involved determines the rate of glycation; some sugars are more reactive than 
others [2, 3, 4, 5]. Glucose, the most abundant sugar in living tissue, has a relatively 
low reactivity. Phosphorylated sugars and carbohydrates with a short carbon chain 
are very reactive. Recent experiments [5] show a remarkably high reactivity of the 
compounds dihydroxyacetone and glyceraldehyde and their phosphates which, 
together with glucose-6-phosphate and fructose-6-phosphate, occur on key positions 
in the anaerobic glycolysis. In vitro experiments with lens proteins have shown a 
possible role for ascorbic acid in the modification of proteins [6, 7]. Not ascorbic 
acid itself, but its oxidation products dehydroascorbate and diketogulonic acid seem 
to be responsible for this type of Maillard reaction [8]. 
The temperature, nature of the incubation medium, accessibility of lysine residues, 
half-life of the protein and, especially, the sugar concentration are important in the 
levels of protein modification. The steps following the ketoamine formation are not 
yet elucidated. A large number of reactions follow, resulting in complex 
carbohydrate-protein complexes. These structures can possess chromophoric and 
fluorophoric properties and are able to crosslink protein chains. These compounds 
are called advanced glycation endproducts or AGE's (stressing the importance of 
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these products in the aging process). The crosslinking properties of AGE's is one of 
the most important consequences of glycation. Some time ago, the structure of a 
glycation endproduct was proposed being a furoyl-furanyl-imidazole compound [9]. 
Profound investigations have shown that this product was generated during the 
isolation procedure and is not actually present in vivo [10, 11, 12]. Only recently the 
structure of an AGE compound was elucidated [13, 14]. This crosslinking group, 
which the authors called pentosidine, is the condensation product of an arginine 
residue, a lysine residue and a pentose. It occurred in a large number of tissues, in 
long living proteins as well as in proteins with a short half-life. The compound was 
present in high levels in tissues with high metabolic activities, reflecting the high 
levels of pentose turn-over. In the human lens, with its low metabolism, only minor 
amounts were present. Hayase et al detected immunologically an acid-labile 
hydroxymethyl pyrrole aldehyde group (which they called pyrraline) on glycated 
proteins [15]. Levels of protein pyrraline immunoreactivity were clearly elevated in 
diabetic subjects. The pyrraline compound has the highly reactive 3-deoxyglucosone 
as intermediate (see below). Probably large numbers of glycation endproducts are 
present in vivo. Though much effort has been undertaken in a search of fluorescent 
products, crosslinking and fluorescent groups are not necessarily linked properties of 
AGE's [16, 17]. 
Physiological consequences 
The glycation of a protein has dramatical results. Early glycation products will 
change the isoelectric point of the protein. This change is even more profound 
when the sugar involved contains a phosphate group. As a result of these changes 
in charge, the molecule can undergo conformational changes. In vitro, this has been 
shown for the eye lens proteins, the crystallins [18]. Especially incubation with 
glucose-6-phosphate resulted in a clear change in the conformation of these proteins 
as revealed by circulair dichroism. Advanced glycation products will cause 
crosslinking of protein chains. In the case of long-lived proteins, this can lead to 
serious complications. In aging individuals, a significant decline in glucose tolerance 
is observed. Age seems to be an independent determinant of glucose tolerance: the 
decline is a primary aging effect and not secondary to other age-associated 
characteristics [19]. The sugar concentrations play a crucial role in the levels of 
protein modification. This indicates the importance of glycation in the etiology of 
patients with diabetes mellitus and galactosemia. The accelerated rate of glycation in 
these patients probably gives rise to a wide range of complications. 
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Glycation of plasma proteins 
The first observation of in vivo glycation concerned the modification of hemoglobin. 
In 1962, Huisman & Dozy [20] showed that the HbAl fraction (containing three 
minor components of human hemoglobin) was increased in diabetic patients. Later 
studies by Fluckinger and Winterhalter [21] demonstrated that Hb Ale could be 
easily fonned in vitro by incubating hemoglobin with glucose. It became clear that 
the level of HbAlc was closely linked with the rate of glycemia of the patient [22, 
23, 24]. Since the early eighties, the measurement of glycated hemoglobin has been 
used clinically as an indicator of glycemia in diabetic patients. Recently, the 
measurement of glycated albumin seems to become more common practice [25, 26]. 
Since albumin has a shorter biological half-life compared with hemoglobin (20 and 
120 days, respectively,) this assay is a short-time indicator of glycemia. Glycation of 
albumin in vivo occurs at multiple sites, Lys-525 being the principal site of 
modification [27, 28]. Other plasma proteins, such as immunoglobulins [29], 
erythrocyte membrane proteins [30], and low-density lipoproteins [31] were found to 
be glycated in vivo. Glycation of LDL had a profound effect on the plasma 
clearance; modifications in the range of 3 to 6% of lysine residues inhibited the 
clearance up to 20% [32]. Glycated low-density lipoproteins and high-density 
lipoproteins are possibly involved in the development of atherosclerosis, a common 
feature in patients with diabetes mellitus [33, 34]. 
Glycation of long-lived proteins 
Crystallins 
The level of modification of a protein depends on the time it is present in the body. 
Proteins with a long biological halflife are, therefore,longer subjected to this process. 
Lens crystallins posses a unique property; they have no turn over at all. Once 
synthesized, they remain in the lens during the total life-span of the individual. As 
aging proceeds, the crystallins become more and more modified by different post-
translational modifications [35, 36]. In patients with diabetes as well in aging 
individuals, cataract is a rather common feature. During cataract formation, the 
crystallins aggregate to form high-molecular weight material, which has severe 
consequences for the transparancy of the lens. As glycation causes crosslinking and 
aggregation of proteins, it might possibly contribute to the development of cataract. 
In animals, there seems to be a correlation between the levels of protein glycation 
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and the amounts of high-molecular-weight material [37, 38]. The glycated proteins 
are enriched in the high-molecular-weight fraction. Human lenses from diabetics 
show a clear increase in glycation products when compared with healthy individuals 
[39, 40, 41]. Glucose is not the only sugar involved in the glycation of crystallins; 10-
20% of the in vivo bound hexose in human crystallins was connected via C-2, 
indicating that the proteins had reacted with fructose [4]. In vitro experiments 
support the hypothesis of conformational changes and formation of high-molecular-
weight material due to glycation [17, 42, 43]. 
An alternative theory on cataract formation is the idea of the polyol pathway, 
introduced by Kinoshita [44, 45]. When in the lenses of diabetic individuals glucose 
levels are elevated, this sugar is converted into sorbitol by the enzyme aldose 
reductase. As sorbitol is unable to cross the lens cell membranes, the osmotic stress 
in these cells is increased dramatically. This could contribute to the damaging of 
lens fiber cells and the development of cataract. Many experiments show that the 
effect of diabetes, except for the increase in the lens of glucose and glucose-6-
phosphate, is a flux of glucose into the polyol pathway initiated by the enzyme 
aldose reductase. Consequently, the flow of glucose through the pentose phosphate 
pathway is enhanced, restricting the glycolytic route in the diabetic lens [46]. The 
importance of the polyol-pathway was underlined by experiments which show the 
prevention of non-tryptophan fluorescence and high-molecular-weight protein 
formation by the aldose reductase inhibitor sorbinil [47]. Interestingly, in this respect, 
is recent work which revealed the presence of fructose 3-phosphate in the lenses of 
diabetic rats [48]. This sugar phosphate, which is not present in normal lenses, is a 
glycating agent and an enzyme inactivator. Fructose 3-phosphate is labile and 
produces upon hydrolysis a highly reactive dicarbonyl compound, 3-deoxyglucosone. 
Collagens 
Another group of long-lived body proteins are the collagens. Though some 
investigators doubt if the low levels of glycation products in vivo could result in 
relevant physical changes in collagens [50], other workers point out that glycation 
might take place at biologically important sites of the molecule, such as the 
collagenase site or glycoprotein interacting sites [51]. The glycation of the glomerular 
basement membrane is particularly well investigated [52, 53, 54]. The consequences 
are, in the case of these basement membranes, more severe compared with fibrous 
collagen; flexibility of the membrane and permeability of the capillaries are clearly 
affected [51]. The binding of fibronectin and heparan sulphate to basement 
membrane collagens is crucial in their functioning in filtration. Interestingly, 
18 
investigators have reported a strong reduction in affinity of these proteins to 
glycated type IV basement membrane collagen [55]. Investigations by Tsilibary and 
co-workers [56] suggest that glycation of the main non-collagenous domain NCI 
(located at the carboxyl end of type IV collagen molecules) may interfere with 
normal assembly of type IV collagen in diabetes mellitus and is possibly related to 
abnormal functions of basement membranes in this pathological condition. Many of 
the observations were done following in vitro glycation; the relevance of these 
processes in the living organism still have to be elucidated. 
As with other body proteins, the levels of early glycation are elevated for skin 
collagens in patients with diabetes mellitus; glycation products were also present in 
normal individuals, in an age-related way [57, 58, 59, 60]. 
Not only the early glycation products are elevated, but also the fluorescent groups 
increased dramatically with age and in diabetes. The only identified structure of an 
advanced glycation product, pentosidine, was first isolated from human collagens 
[13]. It is clear that in vitro glycation of collagens has consequences for its stability, 
solubility and resistance to enzymes [61, 62, 63, 64]. 
Not only internal glycation of collagen occurs, there is also evidence for 
combinations of collagen with non-collagen-protein. Collagens in arterial walls have 
shown to accumulate AGE's and trap normally short-lived proteins [62, 65, 66]. As 
a result, the arterial walls are thickened. Thus, glycation may explain the increased 
appearance of atherosclerosis in both, aging individuals and patients with diabetes. 
Also bone protein, osteocalcin, was found to be glycated in vivo in an age-related 
way [67, 68]. It was established that the site of glycation was the amino-terminal 
tyrosine [68]. Glycated osteocalcin in the bones of aging individuals possibly plays a 
role in the pathogenesis of senile osteoporosis and in osteopenia, seen in diabetes 
mellitus. 
Myelin 
One of the characteristics of diabetic secondary complications is peripheral 
neuropathy, showing segmental demyelination. Myelin has shown to be highly 
glycated in diabetes mellitus [69, 70]. Increased permeability of diabetic endoneurial 
capillaries to plasma proteins, resulting in trapping of these proteins [66], may result 
in peripheral nerve damage. The permeation of glycated albumin into the 
endoneurium of the sciatic nerve of rats was significantly greater compared with 
normal albumin [71]. Glycated albumin enhances its permeation into the nerve, 
19 
which may be relevant in the development of diabetic neuropathy. The possible role 
of macrophages (possessing receptors for AGE's) in this process is discussed below. 
Nucleic acids 
In recent years, pilot experiments have been done to investigate the possibility of 
glycation of the amino groups of DNA bases. Upon in vitro incubation of DNA with 
reducing sugars, it could easily been shown that chromophores and fluorophores 
arise with similar spectral properties when compared with protein-AGE's [72, 73]. 
The reactions proceeded faster with single stranded DNA than with double stranded 
DNA. This modification of DNA has biological consequences; the transfection 
potential of fl phage decreased clearly following in vitro glycation with glucose or 
glucose-6-phosphate [72]. Further evidence for biological relevance of DNA glycation 
came from experiments which showed the mutagenic effect of glucose-6-phosphate 
on plasmid DNA [74]. Some investigators suggest the presence of a precursor 
(composed of lysine and a reducing sugar) before the actual reaction with DNA 
takes place [75]. Others propose a role for radicals (via auto-oxidation of reducing 
sugars) in the modification of DNA [73, 76]. 
Glycation and oxidative processes 
Some investigators argue against the relevance of the Maillard reaction in vivo by 
pointing out that the extent of protein glycation is small in absolute terms: after 120 
days (the average lifespan of an erythrocyte) only 1% of the total amino groups on 
hemoglobin is glycated. In diabetic subjects, this figure increases to about 2.5% [77]. 
Alternatively, Wolff and co-workers developed a theory involving free radicals 
combined with elevated levels of sugars in diabetics. In vitro, small amounts of 
transition metal seemed to be required for sugar-induced non-tiyptophan 
fluorescence [78, 79]. The authors suggest an auto-oxidation of glucose, generating 
peroxides, free radicals and highly reactive dicarbonyl compounds. 
These dicarbonyl compounds (such as 3-deoxyglucosone, which is formed following 
the Amadori conversion [80]) are held at least in part responsible for the 
modifications of proteins in the presence of glucose [81]. 
In vitro experiments with 3-deoxyglucosone produced fluorescent products, 
accelerated polymerization and caused a decrease in enzymatic digestibility of the 
proteins [82]. In rats, administered 3-deoxyglucosone was not biologically utilized, 
but rapidly excreted in the urine [83]. Part of the compound was converted into 3-
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deoxyfructose [83]. Studies of the model compound N(a)-formyl-N(c)-fructoselysine 
(fFL) revealed an oxidative cleavage into N-carboxymethyllysine and erythronic acid. 
This reaction seems also to take place in vivo and occurs by a free radical 
mechanism [84]. Carboxymethyllysine was detected in human lenses and tissue 
collagens [16, 84]. Carboxymethyllysine and N-(carboxymethyl)hydroxylysine (the 
product of oxidation of glycated hydroxylysine) were found in human skin collagen 
in an age-dependent way [85]. This oxidative cleavage of the Amadori-product may 
limit the accumulation of advanced glycation products in vivo. 
Inhibition of the Maillard reaction 
A number of investigators tried to find suitable non-toxic glycation inhibitors. 
Aminoguanidine, a nucleophilic hydrazine compound has frequently been studied in 
its capability to prevent glycation-induced crosslinking. When administered to rats, 
aminoguanidine was able to prevent diabetes-induced formation of fluorescent 
advanced glycation products and inhibited crosslinking of arterial wall connective 
tissue protein [62]. Recent work shows that aminoguanidine does not work on the 
protein, but decreases the concentration of the active aldehyde form of the sugars 
[86]. Aspirin (acetyl-salicylic acid) has an effect on the formation of early and 
advanced glycation products in crystallins [43, 87, 88, 89]. When aspirin was fed to 
rats, formation of lens opacification was considerably delayed, glycation levels 
decreased as well as formation of high-molecular-weight aggregates, while blood 
glucose levels remained the same [89]. Other agents which have shown to be 
effective in inhibition of the glycation of proteins are reduced glutathion [43], 
Ibuprofen (2-[4-isobutyl-fenyl]-propionzuur) [49, 88, 90], Bendazac (1-benzyl-
['HJindazol-S-yl oxyacetic acid) [91] and pyridoxal-5-phosphate [92]. 
There is evidence that the body itself is able to trace, capture and degrade proteins 
containing advanced glycation products. Cerami and co-workers observed that 
macrophages were able to bind and degrade AGE-containing proteins (AGE-BSA) 
via a specific cell-surface binding protein [93]. This receptor was thought to 
recognize the putative furoyl-furanyl-imidazolium compound (FFI), identified by the 
same investigators. The binding protein recognized the carbonyl group, furan rings 
and an imidazolium structure and had a molecular weight of 90 kD [94]. Since later 
experiments revealed that the imidazolium compound does not occur in vivo, the 
involved AGE-structure must resemble the structure of FFI. When formaldehyde-
modified albumin (f-Alb) is injected in rats, a rapid plasma clearance is seen [95]. 
The f-Alb receptor involved, was seen by the authors as a general scavenger 
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receptor for aldehyde-modified proteins. The cellular binding of AGE-BSA in cell 
cultures mentioned above, was indeed inhibited by addition of f-Alb [96, 97]. f-Alb 
had also a profound in vivo effect on the plasma clearance of AGE-BSA in rats. 
Remarkably, FFI and its BSA-conjugates did not influence binding or plasma 
clearance of the AGE-BSA, which makes the involvement of FFI in the receptor-
mediated uptake of advanced glycation products unlikely [96]. 
The removal and uptake of AGE-proteins seems to be associated with the 
production and secretion of TNF(tumor necrosis factor or cachectin) and IL·! 
(interleukin-1) [98]. The authors suggest that crosslinked senescent proteins are 
removed by cytokine-dependent proteases after recognition by macrophages which 
initiate secretion of cytokines like TNF and IL·!. Recent data report an 
upregulation of the macrophage/monocyte receptor for glycated proteins by 
cachectinATiF [99]. AGE's induces human monocyte Chemotaxis and the secrection 
of platelet-derived growth factor [100]. These data support the hypothesis that 
AGE's can act as signals for the turnover of senescent proteins via a specific 
receptor system. 
Though glycation has a profound effect on proteins in vitro, and the reaction occurs 
in every living organism, it is not yet clear to which extent it is responsible for the 
complications seen in diabetics and aging individuals. Glycation occurs on a large 
scale in vivo with a most apparent effect on long-lived molecules. Possibly, glycation 
is just one factor in a series of modifications. Remarkably, food restriction in rats 
shows retarded age-related processes, increase of mean and maximal lifespan and 
lower levels of glycated hemoglobin [101, 102]. These results, together with the fact 
of faster development of age-related processes in diabetics, strongly support the idea 
of a role for reducing sugars in the aging process. 
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GLYCATION-INDUCED CROSSLINKING OF CALF L£NS CRYSTALLINS 
SUMMARY 
To investigate the possible role of gtycation in the onset of diabetic cataract we used 
calf lens crystallins as a model. After incubation with reducing sugars, the proteins were 
investigated by high-pressure gel permeation chromatography, SDS-PAGE and analytical 
ultracentrifugation. Glucose-6-phosphate incubation resulted in an increase in mean 
molecular weight of all crystallin fractions and the occurrence of high-molecular-weight 
material, partly formed by disulfide bonds. The glycated crystallins showed a decrease of 
tryptophan fluorescence and an increase of a specific non-tryptophan fluorescence. This 
fluorescence was, however, not exclusively associated with the high-molecular-weight 
protein, but was present in all protein fractions. 
key words : glycation: high-molecular-weight protein; calf lens; crystallins; 
crosslinkmg. 
INTRODUCTION 
Glycation, formerly called non-enzymatic glycosylation, is a post-synthetic 
modification of proteins. Originally, the reaction was only studied in the field of 
food chemistry (Maillard. 1912; Pinot, 1982; Saltmarch and Labuza, 1982). Later 
experiments revealed glycation to affect a wide range of body proteins (for review 
see Krantz, Lober and Henschel, 1986). Glycation is especially important in 
individuals with elevated blood sugar levels (diabetes mellitus, galactosaemia) and 
may play a role in the secondary complications of diabetes such as atherosclerosis 
and cataract. The initial reaction takes place at the free amino groups of the 
protein (N-terminal amino acid or the ε-ΝΗ2 group of lysine) and results in the 
formation of an unstable Schiff base which rearranges to the so-called Amadori-
product. This Amadori-product undergoes a number of unspecified dehydration and 
rearrangement reactions. The final glycation products are in general crosslinked, 
pigmented and fluorescent carbohydrate-protein complexes. Some years ago, Pongor 
et al. (1984) claimed to have isolated a glycation crosslink product called FFI [2-(2-
furoyl)-4(5)-(2-furanyl)-lH-imidazole] from the acid hydrolysate of glycated polylysine 
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and glycated bovine serum albumin. However, according to recent experiments by 
Njoroge, Fernandos and Monnier (1988), FFI is formed from ammonia and furosine 
which are by-products of acid-hydrolysed glycated proteins. These findings have been 
confirmed by other investigators (Horiuchi et al., 1988; Huber, Ledi and Severin, 
1988) and form strong evidence against the presence of FFI in glycated proteins. In 
this study, the crosslinking and fluorescence of glycation products, as well as the 
levels of early glycation products and the possible role of disulphide bond formation 
are investigated. For these in vitro experiments we used calf lens ciystallins as a 
model. The possible role of glycation in the onset of cataract is discussed. 
MATERIALS AND METHODS 
Isolation of calf lens ciystallins 
Calf lenses were obtained from the slaughter house. The lenses were decapsulated 
and gently stirred at 4°C for 15 min in a phosphate buffer (20 mM sodium 
phosphate, 100 mM sodium sulphate and 1 mM EDTA, pH 6.9) to dissolve the 
outer cortex. The suspension was centrifuged at 10,000 rpm for 30 min to remove 
the water-insoluble material. The water-soluble crystallins were dialysed against 
deionized water, lyophilized and stored at -20° С until further use. 
Incubation of calf lens ciystallins 
Protein 50 mg ml'1 was dissolved in a phosphate buffer (100 mM sodium phosphate, 
pH 7.3) containing 100 mM glucose (Merck, Darmstadt), glucose-6-phosphate 
(Merck) or galactose (Merck). NaN, (0.05%) was added to prevent bacterial growth 
and all samples contained 1 mM EDTA. A control sample with no sugar added was 
incubated simultaneously; incubations were performed at 37* С and continued for 14 
days. 
Absorption and fluorescence spectra 
Absorption spectra were taken from 200 to 800 nm using a Hitachi 150-20 
spectrophotometer. Fluorescence spectra were taken using a Perkin-EImer 204-A 
spectrofluorometer. 
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SDS/Polyaciylamide electrophoresis 
SDS-PAGE was performed using 15% slab gels and 4% stacking gels. 
High-pressure gel permeation chromatography (HPGPC) 
HPGPC was performed using combined Zorbax GF450/GF250 columns (DuPont, 
Den Bosch, The Netherlands) guarded with a PWH column (Chrompac). Elution 
buffer (20 mM sodium phosphate, 100 mM sodium sulphate, 1 mM EDTA, pH 6.9) 
and samples were filtered over a 0.2 μπι filter prior to use. The elution buffer was 
degassed with helium. Detection was performed with a differential refractive index 
detector (DRI; Melz-LCD-201) a spectrophotometer (Hitachi 100-30) and a 
spectrofluorometer (Perkin-Elmer 204-A). Absorption was monitored at 280 nm; 
fluorescence with excitation 290 nm and emission 340 nm (tryptophan fluorescence) 
or excitation 370 nm and emission 440 nm (specific non-tryptophan fluorescence) 
wavelenghts. 
Analytical ultracentrifugation 
Sedimentation analyses of incubated samples were performed with a Beekman 
Spinco model E analytical ultracentrifuge, equipped with electronic speed control 
and Schlieren optics. Analysis temperature was around 20° С Sedimentation 
coefficients were corrected for the density and viscosity of the buffer relatively to 
water at 20° С 
Quantitation of early glycation products 
The amount of protein bound sugar was determined by measuring the 
hydroxymethyl furfural (HMF) release after mild hydrolysis with oxalic acid. To 0.5 
ml of a protein solution (10 mg ml"1), 0.250 ml M oxalic acid was added and 
incubation was performed at 100° С for 4.5 hr. Then, 0.250 ml 40% TCA was added 
and samples were centrifugated for 5 min in a Beekman Minifuge to precipitate the 
protein. Supematants were analysed on a C,, reversed-phase column (Bondapack) 
using 5 mM HjP04 as an effluent and detecting the absorbance at 280 nm. For 
quantification of the HMF release, standard samples of HMF (Aldrich, Brussels, 
Belgium) were injected. 
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RESULTS AND DISCUSSION 
To investigate the effect of glycation, calf lens crystallins were incubated at 37* С 
with glucose (Glc), glucose-6-phosphate (Glc-6-P) or galactose (Gal). After 14 days, 
the Glc-6-P incubated sample showed considerable browning compared with the 
control. The Glc- and Gal-incubated samples showed no visible change in color. To 
determine the presence of chromophores and/or fluorophores, we recorded 
absorption and fluorescence spectra. 
I 500 
200 300 4 0 0 500 600 700 
Wavelength (nm) 
Figure 1 Absorption spectra of the Glc-6-P 
incubated sample (upper line) and the 
control sample 
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Figure 2 Excitation and emission spectra of Glc-
6-P incubated calf lens crystallins 
As shown in Fig. 1, the Glc-6-P-incubated sample revealed a change of the 
absorption spectrum in the 300-400 nm region. There appeared to be two maxima 
of 335 and 370 nm (see insert). Fluorescence studies revealed a strong increase of a 
specific non-tiyptophan fluorescence for the Glc-6-P-incubated sample. The 
excitation and emission wavelengths were 370 and 440 nm, respectively (Fig. 2). The 
Glc- and Gal-incubated samples showed no significant changes in absorption or 
fluorescence properties. 
3 5 
The chromophore with an absorption maximum of 370 nm corresponds with the 
results found for in vitro glycated products such as BSA and polylysine (Pongor et 
al., 1984) and in human crystallins (Monnier and Cerami, 1983). This wavelength 
corresponds with the excitation maximum of the fluorophore. Experiments 
performed by Beswick and Harding (1987) revealed increased absorption at 450 nm. 
However, these experiments were performed solely withT-ciystallin and may reflect 
chromophores which are specific for 7-crystallins. 
Glc-6-P is far more effective in producing early and advanced glycation products 
compared with Glc and Gal. Determination of early glycation products (using the 
hydroxymethyl furfural assay) (Van Boekel and Hoenders, 1990) revealed a strong 
increase, up to tenfold compared with controls, in the Glc-6-P incubated sample. 
Incubation with Gal resulted in a more moderate increase in ketoamine content 
(threefold compared with controls). The Glc-incubated sample showed only a slight 
increase in early glycation products. These and other results (see below) show that 
incubation with Glc-6-P results in rapid formation of early and advanced glycation 
products, whereas incubation wirth Glc and Gal under these conditions has not yet 
resulted in the occurrence of advanced glycation products. 
Based on these findings, we tried to determine the effect of glycation on the 
individual crystallin fractions. We fractionated the total crystallin sample by HPGPC 
and monitored the effluent with DRI, absorption (Α^,), tryptophan fluorescence 
(290/340nm) and specific non-tryptophan fluorescence (370/440 nm). The results are 
shown in Fig. 3. 
The incubations with Glc and Gal showed no remarkable differences compared with 
the control. The Glc-6-P incubated crystallins showed a strong decrease in 
tryptophan fluorescence and a dramatic increase in non-tryptophan fluorescence 
[Figs 3(C) and (D)]. Incubation with Glc-6-P led to the disappearance of the 
original a-crystallin peak and the appearance of a peak with shorter elution time 
[Figs 3(A) and (B)]. After the new peak, a heterogeneous mixture of crystallins was 
eluted at approximately 43-52 min. In a position between the peaks of β
Η
 and ßL-
crystallin another peak arose (55 min), whereas the β- and 7-peaks made way for an 
uncharacteristic, flattened elution profile. Compared with the profile of the control 
sample, a shift towards shorter elution times is clearly visible. This suggests that all 
crystallins are subjected to crosslinking processes. 
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Figure 3 H i g h - p r e s s u r e g e l p e r m e a t i o n 
chromatography of sugar-incubated ca l f 
l e n s c r y s t a l l i n s , d e t e c t i n g absorpt ion 
a t 280 nm (A) , DRI (Β) , t ryptophan 
f luorescence (C) and non-tryptophan 
f luorescence (D). 
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Figure 4 Sedimentation velocity analysis of the 
control (A) and the Glc-6-P-incubated 
sample (B). Sedimentation is from left 
to right for 24 min at 60000 rpm. 
These findings were confirmed by analytical ultracentrifugation (Fig. 4). The a-, j9H-
and 0L-peaks are visible in the control. Under the applied conditions, 7-crystallin is 
not separated from the meniscus. In the case of the Glc-6-P-incubated sample, the 
fast moving peak has become asymmetrical, the /JH- and /3L-ciystallin peaks have 
made way for one peak and the area between the peaks demonstrates the presence 
of a heterogeneous protein mixture. The sedimentation coefficient of the fast 
moving component could be measured and amounted to 12.7 ± 0.1 S and 14.5 ± 
0.2 S for the control and the Glc-6-P-incubated sample, respectively. This means 
that there is a significant difference between the mean molecular weights of a-
crystallin and the fast moving material formed by the in vitro glycation procedure. 
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Prolonged incubation with Glc and Gal eventually also resulted in protein 
crosslinking. The first part of the high-molecular-weight peak obtained by HPGPC 
was analysed on SDS-PAGE (results not shown). In addition to highly crosslinked 
protein, which remained on top of the gel, this sample also contained free a- and ß-
crystallin subunits and, presumably, 7-crystallin. 
To investigate whether disuiphide bridges played a role in the Glc-6-P-induced 
crosslinking, 100 mM DTE was added and incubation was carried out at 37" С for 
30 min. Another portion of the sample was treated overnight with NaBH4 (40 mM) 
to investigate the influence of early Maillard products. The excess NaBH4 was 
removed by extensive dialysis against the 100 mM phosphate buffer. The samples 
were analysed on the HPGPC system, detecting the Aj» and the non-tryptophan 
fluorescence (Fig. 5). 
-J ι I I ι L 
45 55 45 55 
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Figure 5 H i g h - p r e s s u r e g e l p e r m e a t i o n 
chroroatography of t h e Glc-6-P-incubated 
sample before (upper l i n e ) and a f t e r 
t reatment with NaBH4 or DTE, d e t e c t i n g 
Aja, (A) and non-tryptophan f luorescence 
(B). 
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The treatment with NaBH, had no remarkable effect on the HPGPC patterns. 
Treatment with DTE partly dissociated high-molecular-weight material, causing an 
increase in the β- and 7-crystallin range. Thus Glc-6-P seems to be able to crosslink 
crystallins, in which at least part of this crosslinking is caused by disulphide bonds. 
To verify this finding, we analysed the incubated samples on SDS-PAGE, with and 
without DTE in the sample buffer (Fig. 6). 
14 
s г Î 4 м ι г î 4 
Figure 6 SDS Polyacrylamide gel electrophoresis 
of sugar- incubated calf lens 
crystallins, with (+) or without (-) 
DTE in the sample buffer. Lanes: 1, 
Glc-6-P; 2, Glc; 3, Gal; 4, control; M, 
Markers (Phosphorylase b, 97 kD; bovine 
serum albumin, 66 kD; ovalbumin, 42 kD; 
carbonic anhydrase, 31 kD; trypsine 
inhibitor, 21 kD and lysozyme, 14 kD)· 
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The crosslinking by Glc-6-P is evident; however, only part of this crosslinking can be 
abolished with DTE. Glc-6-P is able to cause conformational changes in crystallins 
(Liang and Chakrabarti, 1981; Beswick and Harding, 1987; Liang, 1987; Liang and 
Ross, 1990). As a result, -SH groups might be exposed as an initiation for disulphide 
crosslinking. The decrease of tryptophan fluorescence in our experiments could be 
explained by an altered environment of the tryptophan groups due to 
conformational changes. The contribution of disulphide bridges to the formation of 
high-molecular-weight protein due to glycation is controversial (Monnier et al., 1979; 
Ansari, Awasthi and Srivastava, 1980; Monnier and Cerami, 1982; Liang and 
Chylack, 1984; Beswick and Harding, 1987; Репу, Swamy and Abraham, 1987). Our 
experiments, however, indicate the occurrence of high-molecular-weight material 
partly as a result of disulphide bridges. 
In HPGPC patterns, the non-tryptophan fluorescence of the Glc-6-P-incubated 
sample follows more or less the DRI or absorption pattern and is not exclusively 
present in the high-molecular-weight material (Fig. 3). This could be explained by 
the presence of fluorophoric crosslinks between individual subunits in a crystallin 
molecule or even intra-chain crosslinks. Another possibility is that the fluorescent 
group is not involved in crosslinking, but is formed by a rearrangement of the 
attached sugar in e.g. pyrrole compounds (Njoroge, Sayre and Monnier, 1987; 
Hayase et al., 1989). When we incubated human serum albumin with Glc-6-P and 
analysed the sample by HPGPC, the non-tryptophan fluorescence was almost 
completely associated with the monomer; the minor amount of dimer revealed only 
a proportional amount of non-tiyptophan fluorescence (results not shown). These 
results suggest that, in most cases, fluorescence and crosslinking are not joint 
properties of advanced glycation products. Interesting, in this respect, is the finding 
by Dunn et al. (1990) of a fluorescent Maillard product (MFP-1) detected in model 
systems as well as in human lens proteins. Although this compound has fluorescent 
and crosslinking properties, it accounted for less than 1% of the glycation-induced 
crosslinking of the protein. These experiments suggest that the major crosslinks 
formed during the Maillard reaction are non-fluorescent compounds. 
Both Glc and GIc-6-P levels are elevated in the diabetic lens (Gonzalez, Sochor and 
McLean, 1980). Considering the high reactivity of Glc-6-P with crystallins, glycation 
probably plays a role in the onset of diabetic cataract. The level of early glycation 
products is elevated in the lens of diabetic patients, compared with normal 
individuals (Kasai et al., 1983; Garlick et al., 1984; Lee et al., 1984; Liang, 
Hershorin and Chylack, 1986; Rao and Collier, 1986; Oimomi et al., 1988). The 
presence of advanced glycation products involving crosslinks is only poorly 
understood. Recently, Oimomi et al. (1988) detected a glycation-related fluorophore 
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in cataractous lenses of both non-diabetic senile subjects and diabetic patients. The 
amount decreased in the order nucleus > cortex > capsule, but was not significantly 
higher in the lenses from diabetic patients. 
The nature and structure of most chromophonc and fluorophoric groups of the 
glycation reaction are unknown. Recently, Sell and Monnier (1990) elucidated the 
structure of a pentose-induced glycation crosslink which they called pentosidine. This 
structure, which was composed of lysine, arginine and a pentose, was detected in a 
large variety of tissues, and showed an age-related accumulation. Since FFI probably 
does not occur in vivo, the structures of any hexose-induced glycation crosslinks are 
not yet known. 
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IN VIVO GLYCATION OF BOVINE LENS CRYSTALLINS 
SUMMARY 
To investigate the possible role of glycation in the aging of lens proteins, we used bovine 
lenses as a model. We studied crystallins isolated from prenatal bovine lenses, calf 
lenses and lenses from mature animab (up to 20 years old). In general, lenses were 
divided into cortex and nucleus. Vie crystallin fractions were separated into high-
molecular-weight (HAf) material, α-, β- and J-crystallin, using gel permeation 
chromatography. 
The experiments show an increase in glycation leveL· with age in all crystallin fractions. 
The results revealed high levels of early glycation products for the HM material 
(containing mainly a-crystallin). In a-crystallin, aA subunits were glycated to a higher 
extent compared with the aB subunits. Regarding the lysine content of the different 
crystallins, y-crystallin showed relatively high levels of early glycation products. There L· 
an age-related increase in advanced glycation products, measured as specific 
fluorescence (excitation/emission wavetenghts 3701440 nm), mainly present in the HM-
and a<rystallin fraction. 
INTRODUCTION 
The process of non-enzymatic glycosylation (glycation) is, although it was already 
discovered in 1912 by Louis Maillard, under intensive current investigation. 
Glycation involves the reaction of a reducing sugar with the amino-group of a 
protein. After rearrangement of the Schiff-base to the Amadori-product, further 
unknown reactions take place, resulting in carbohydrate-protein complexes with 
fluorescent features or crosslinking properties (see for a review on the chemical 
pathways: Njoroge et al., 1989). Only recently, the structure of such an advanced 
* Abbrevations: HM, high-molecular-weight material; SDS-PAGE, sodium dodecyl 
sulphate - Polyacrylamide gel electrophoresis; EDTA, ethylene diamino tetra-acetate; 
HPGPC, high-pressure gel permeation chromatography; BCA, bicinchoninic acid; WS, 
water-soluble; US, urea-soluble. 
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glycation product called pentosidine was elucidated (Sell an Monnier, 1989; Monnier 
et al, 1990). Late glycation products accumulate in vivo, possibly contributing to the 
pathology in diabetes and aging (Monnier et al., 1990; Van Boekel, 1991). Especially 
proteins with a long biological half-life, such as the eye lens proteins (crystallins) will 
build up relatively large amounts of glycation products. When analyzed on SDS-
PAGE and isoelectric focusing gels, crystallin fractions show a remarkable increase 
in heterogeneity at the subunit level with age. There is evidence for a number of 
crystallin modifications occurring in vivo such as oxidation, deamidation, 
phosphorylation, carbamylation, racemization of aspartic acid residues, disulfide 
crosslinking and glycation (see for reviews Hoenders and Bloemendal, 1981; 
Hoenders and Bloemendal, 1983; de Jong et al., 1988; Harding et al., 1989). The 
content of early glycation products in lenses is controversial; while some investigators 
report a strong age-related increase of the Amadori-product content (Chio et al., 
1981; Garlick et al., 1984), others determined only a minor increase in lenses of 
different age (Swamy and Abraham, 1987; Perry et al., 1987; Baynes et al., 1989; 
Lyons et al., 1990). In our experiments, we determined the levels of early glycation 
products (using tritium-labeled NaBH4) and advanced glycation products (measuring 
specific fluorescence). 
MATERIALS AND METHODS 
Isolation of bovine crystallins 
Calf lenses and lenses from bovine fetuses were obtained from the local 
slaughterhouse. Lenses from cows were kindly provided by Dr J Bours (Bonn). 
Lenses were divided into cortex and nucleus and suspended in buffer (20 mM Tris-
HC1 pH 7.3, 80 mM NaQ, 1 mM EDTA). Lenses from fetal animals were used as 
a whole. The water-soluble and water-insoluble fractions were separated using a 
Beekman Minifuge (5 minutes). The pellet was washed twice to remove all water-
soluble material. The urea-soluble proteins were obtained by treatment with the 
same buffer containing 6 M urea. 
Gel permeation chromatography 
The crystallin fractions were separated using different gel permeation columns. In 
general, the first separation was done using an AcA34 (Pharmacia-LKB) or a 
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Superóse 6 (Pharmacia-LKB) column. In some cases, β- andT-crystallins were 
separated using a Sephadex G75 (superfine) column (Pharmacia). For separation of 
HM material from a-crystallin, a Biorad A5m column was used. All crystallin 
fractions were dialyzed against distilled water and lyophilized. 
High-pressure gel permeation chromatography (HPGPC) 
HPGPC was carried out at room temperature using Zorbax 450/250 colums 
(duPont) and a TSK G5000 PW column, preceded by a TSK guard column 
(Biorad). Elution was performed with a flow of 0.4 ml/min using a phosphate buffer 
(0.1 M NazSO« 1 mM EDTA and 20 mM Na-phosphate, pH 6.9). Detection was 
done using absorbance (280 nm) or fluorescence (excitation/emission wavelengths 
370/440 nm). 
Separation of aA and aB subunits 
The separation of aA- and oB-subunits was carried out as described by Stevens and 
Augusteyn (Stevens and Augusteyn, 1987; Augusteyn et al., 1988). Briefly, bovine a-
crystallin was dissolved in a glycine-HCl buffer pH 2.5. This results in a fairly 
specific dissociation of aB from the crystallin aggregate. Separation was performed 
on a Sephadex G75 (superfine) column. 
NaBH, reduction 
Protein samples were obtained by dissolving 2 mg protein in 1 ml phosphate buffer 
pH 7.3. [3H]-NaBH4 (Amersham) was used for these experiments. After addition of 
the labeled reagent, the sample was incubated for 30 minutes at 40C and 60 
additional minutes at room temperature. By adding acetic acid, the pH was lowered 
to 4-5 in order to destroy the bulk of unreacted NaBH4. The samples were 
extensively dialyzed against phosphate buffer (in some experiments containing 6M 
urea) to remove remaining traces of NaBH,. The amount of incorporated label was 
measured and protein concentration was determined using the BCA assay (Pierce). 
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RESULTS AND DISCUSSION 
Gel permeation chromatography was performed to obtain crystallm fractions from 
bovine lenses of different age. The composition of the crystallin population differs 
significantly with age. Upon agmg the peaks of the elution pattern representing a-, 
β- and 7-crystallm are flattened and elution times are altered, reflecting the increase 
in heterogeneity as a result of posttranslational modifications. 
Determination of early glycation products was done using NaBH, as a reducing 
agent. This marks both the Schiff base and the Amadon product. The results are 
summarized in Figure 1. 
cpm/mg protein MOOO) 
fetal calf cow β years cow 20 years 
HM E M A I p h · (ZZI Bala high Ш Bata low d û Gamma 
Figure 1 Incorporation of radioactivity in 
bovine WS crystallins "bfter 
treatment with ['HJ-NaBlb 
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If expressed as cpm/mg protein, there are no dramatical differences between α-, ß-
and 7-crystallin fractions. However, 7-ciystallin has a much lower lysine content, on 
average one-fourth compared with that of a- en ß-crystallin. Harding et al. (1988) 
found a preferential glycation of the N-terminal glycine in bovine 7-crystallin by in 
vitro glycation with glucose-6-phosphate. This suggests that this terminal amino group 
is responsible for the high levels of glycated 7-ciystallin. Whereas a- and 0-crystallins 
have quaternary structures, 7-crystallin is monomenc. This may facilitate the 
accessibility of amino groups for glycation. In vitro experiments and studies with 
diabetic rats revealed rapid glycation of 7-crystallin (Swamy and Abraham, 1991). In 
long-term experiments, a- and 0-crystallins glycated slowly during the early stage, 
followed by a steep increase during the remainder of the experimental period. 
Comparison of the WS and the US fractions revealed higher glycation levels for the 
latter (results not shown). This difference seems to become more prominent with 
increasing age. 
The HM fraction showed the highest level of glycation in all lenses (Figure 1). The 
lenses of 4-month-old fetuses contained no significant amounts of HM. The high 
levels of glycation of HM suggest a shift of glycated crystallins towards the HM 
fraction, presumably as a result of conformational changes and partial unfolding of 
the protein (Beswick and Harding, 1987). As a result of these changes, thiol groups 
could become more exposed, which facilitates aggregation and the formation of HM. 
HM in bovine lenses is mainly composed of a-crystallin. Since the levels of glycation 
products in the original a-crystallin peak are not extremely high, glycation of a-
crystallin possibly causes partial unfolding and a tendency to form HM aggregates. 
We further investigated the intra-molecular glycation of a-crystallin from calf lenses 
by separation of the aA and aB subunits. The results are shown in Figure 2. 
Exposure of a-crystallin to 0.1 M glycine pH 7 decreases the molecular weight of 
the protein from 800 kD to 420 kD (Augusteyn et al., 1988). Lowering of the pH to 
2.S in the same buffer results in dissociation of the aggregate in monomeric aB 
chains (slightly contaminated with aA chains) and an aggregate of 290 kD containing 
only aA chains (Augusteyn et al., 1988). The aggregate and the monomeric aB 
chains were separated on a Sephadex G7S superfine column (Figure 2). Surprisingly, 
the material from the first peak contains the highest level of reducible groups. 
This may mean that the aggregate of aA chains is glycated to a higher degree 
compared with the aB chains of the molecule. These findings are remarkable, since 
the аВ-chains contain more lysine groups than aA-subunits (10 and 7, respectively). 
Within the first peak the fast eluting material, representing protein with higher 
molecular weight, incorporated more radioactivity compared with the remaining aA 
subunits (Figure 2c). 
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Figure 2 Glycation of oA and aB subunits 
a) Separation of аА- and oB-crystal l in 
subunits on Sephadex G75 (superfine) 
using 0.1 M glycine-HCl buffer pH 2.5. 
From each co l lected fraction, 20 μΐ was 
taken for measurement of radioact iv i ty . 
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lllllll 
Previous work in our laboratory resulted in a model for the quaternary structure of 
a-crystallin (Siezen et al., 1978; Bindeis et al., 1979; Siezen et al., 1979). In this 
model, αΒ chains are located in the outer region of the aggregate, which would 
make them relatively susceptible to modifying agents. So far, we have found no 
clear explanation for the preferential glycation of the oA aggregate. Possibly, rapid 
in vivo glycation of αΒ results in further reaction to advanced glycation products. 
Indeed, α-crystallin shows high levels of specific non-tryptophan fluorescence (see 
below) in spite of relatively low levels of early glycation products. Experiments by 
Van den Oetelaar et al. (1990) made clear that a-crystallin molecules have the 
ability to exchange subunits. This phenomenon, postulated as the "dynamic 
quaternary structure" of a-ciystallin could form the key to explain the age-related 
increase in molecular weight of the molecule. Interestingly, in this respect, is recent 
work by Liang and Rossi (1990) which shows that α-crystallin, upon glycation, 
becomes thermodynamically less stable, facilitating the loosening of subunits from 
the molecule. 
500 1000 1500 2000 2500 
fetus 
calf 
cow (6 years) 
cow (20 years) 
^ ^ ^ 
500 1000 1500 2000 2500 
HM alpha ] 
Figure 3 N o n - t r y p t o p h a n f l u o r e s c e n c e 
(wavelengths 370nm/440 nm) of t h e high-
molecular-weight-material and t h e a-
c r y s t a l l i n f r a c t i o n obtained from 
lenses of d i f f e r e n t age. 
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For the determination of advanced glycation end products, we used the non-
tryptophan fluorescence (wavelengths 370/440 nm) as a parameter. Previous 
investigations showed an increase of this specific fluorescence for in vitro 
experiments (Van Boekel and Hoenders, 1991). Our results show dramatically high 
levels of fluorescence in the HM material and the a-crystallin fraction (Figure 3). 
The other crystallin fractions showed only minor amounts of fluorescent groups in 
the 20-year old material (not shown). The levels of fluorescence were strongly age-
dependent (Figure 3). These results suggest a prominent role for a-crystallin in the 
glycation of crystallins. 
Protein crosslinking and formation of HM is characteristic for the initiation of 
cataract, one of the main complications seen in patients suffering from diabetes 
(Van Boekel, 1991). There is evidence that glycation can induce non-disulfide as 
well as disulfide crosslinking of protein chains (Van Boekel and Hoenders, 1991). 
Changes in protein structure induced by the attachment of sugars could easily 
expose thiol groups, thus facilitating disulfide crosslinking and formation of HM-
material. When considering the modification of crystallins in relation to cataract, 
oxidative processes are also thought to play a role. Oxidation of glycation products 
has been demonstrated in vitro and oxidative degradation products of glycated 
proteins have been identified in human lenses (Ahmed et al., 1988). Reducing 
sugars could also modify proteins in an indirect way: Wolff and co-workers (Wolff et 
al., 1989) suggest an auto-oxidation of sugars resulting in the generation of free 
radicals. These radicals could cause severe protein damage, initiating protein 
crosslinking and fragmentation. Modification of crystallins in aging and diabetes, 
eventually leading to cataract, probably involves several interacting mechanisms. 
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GLYCATION OF CRYSTALLINS IN LENSES FROM 
AGING AND DIABETIC INDIVIDUALS 
SUMMARY 
Water-soluble crystallins were obtained from clear human lenses of different age (4- to 
Sl-years-old) and lenses of individuals showing senile or diabetic cataract. Early 
glycation products as well as fluorescent late glycation products were determined in all 
crystallin fractions. Levels of early glycation products were high in the high-molecular-
weight material (HM@) and the a-crystallins fractions, compared with β- and y-
crystallins. Tliis difference becomes more prominent upon aging. The content of total 
early glycation products in HM and a<rystallin increases clearly with age, whereas levels 
remain relatively constant in the β- and "i<rystallins. Viere is an elevation of early 
products in cataractous lenses from diabetic individuals compared with those suffering 
from senile cataract. Specific поп-tryptophan fluorescence (excitation/emission 
wavelenghts 370l440nm), used as an indicator for late glycation products, increased 
dramatically with age and was two-fold higher in the diabetic subjects. Levels of 
fluorescence decreased in the order HM > a- > β- >У -crystallins. The results suggest 
an increase in glycation rate in a-crystallin as a result of aging and diabetes, while the 
rate of glycation of β- and У-crystallins remains almost constant. Viese findings support 
the idea of a role for glycation in age-related changes in crystallins (especially a-
crystallin) and the development of diabetic cataract. 
INTRODUCTION 
Crystallins are a popular object for the investigation of post-translational protein 
modifications. In the lens, almost no protein is actively degraded: all synthesized 
proteins, back to the embryonic stage of the individual, remain present. The oldest 
* Abbrevations : HM, high-molecular-weight material, EDTA, ethylene diamino 
tetra-acetate; HPGPC, high-pressure gel permeation chromatography; BCA, 
bicinchoninic acid; WS, water-soluble; US, urea-soluble; SD, standard deviation. 
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proteins are located in the center, while a decrease in age is seen towards the 
cortex of the lens. Due to this unique property, the lens is an ideal object for 
studies of age-related changes in proteins. As aging proceeds, several changes take 
place in the lens accumulating in coloration and opacification of the lens (Spector et 
al., 1975; Zigman et al., 1976; Harding and Crabbe, 1984). A number of post-
translational modifications including oxidation, deamidation, racemization and 
glycation have been demonstrated to occur in vivo (Harding, 1985). Glycation, 
which involves the reaction of a reducible sugar with a free amino protein group, is 
especially important in diabetics. Possibly, this feature is the cause of cataract which 
is a common complication in diabetics (Van Boekel, 1991). Reducing sugars have 
shown to be able to initiate crosslinking of crystallins in vitro, partly as a result of 
disulfide bonds (Liang and Rossi, 1991; Van Boekel and Hoenders, 1991). Glycation 
products are divided in early modification products (this includes the NaBH,-
reducible Schiff base and the ketoamine or Amadori-product) and late glycation 
products. The latter are characterized by fluorescent properties, sometimes 
combined with protein cross-linking. We investigated glycation on crystallins from 
lenses ranging from 4- up to 81-years-old. Early glycation was determined using 
radiolabeled NaBH4. Advanced glycation products were studied using specific 
fluorescence as a parameter. Additionally, lenses from senile and diabetic 
cataractous individuals were used in an attempt to clarify the role of glycation in 
diabetic cataract. 
MATERIALS AND METHODS 
Lenses 
Clear human lens (4- to 81-years-old) were provided by the Ophthalmic Research 
Institute (Amsterdam). Lenses from subjects with senile or diabetic cataract were 
obtained from the Eye Clinic of the Free University of Berlin. Lenses were 
decapsulated and homogenized in phosphate buffer (140 mM NaCl, 3 mM KCl, 8 
mM КНгРО« 1.5 mM NaiHPO, adjusted to pH 8.1 with HCl). Clear lenses were 
used individually, cataractous lenses were pooled in two groups: senile cataract (77, 
77, 78, 78 and 78 years of age) and diabetic cataract (76, 76, 76, 78 and 78 years of 
age). The insoluble material was removed by a 5 minute centrifugation in a 
Beekman Microfuge В. 
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[ΉΙ-NaBH« reduction 
Samples were reduced by a [3-H]-NaBH4 solution (Amersham) and were allowed to 
react 10 minutes at room temperature, followed by an incubation of 90 minutes at 
4" С Unreacted NaBH, was removed by extensive dialysis against phosphate buffer 
(140 mM NaCl, 3 mM KCl, 8 mM KH2P04, 1.5 mM Na^PO,, pH 7.3) until 
radioactivity in the dialysis buffer was negligible. The labeled proteins were 
separated using high-pressure gel permeation chromatography (HPGPC). 
High-pressure gel permeation chromatography 
HPGPC was performed using combined Zorbax 450/250 columns (both 28 cm, 
DuPont) preceded by a guard column (Biorad). Elution was performed using a high-
salt phosphate buffer (20 mM Na-phosphate, 100 mM Na^O,, 1 mM EDTA pH 
6.9) with a flow of 0.8 ml/minute. Detection was done by measuring the absorbance 
at 280 nm (Hitachi 100-30 spectrophotometer) and fluorescence (excitation 
wavelength 370 nm, emission wavelength 440 nm; Perkin-Elmer 204-A 
spectrofluorometer). The eluting material was collected and incorporated label was 
determined by counting 0.6 ml of each fraction using a liquid scintillation counter 
(2200 TRICARB, Packard). Protein concentrations were determined using the BCA 
assay (Pierce). 
RESULTS 
Water-soluble proteins of lenses of different age were investigated for the presence 
of early glycation products using [3H]-NaBH4. Crystallin fractions were separated 
using HPGPC; a typical chromatography pattern is shown in Figure 1. 
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τ 
30 
Elution time (mm) 
Figure 1 Elution pattern of the water-
soluble proteins of a 38-year-old 
lens after reduction with NaBH,. 
Detection was performed measuring 
Ajw and specific fluorescence. 
With increasing age, the height of the HM peak increases clearly. There was also a 
strong increase of the height of the 7-peak in the older lenses. The eluting material 
was collected and the amounts of radioactivity and protein concentration were 
determined. The content of early glycation products in HM, α-, β- and 7-crystallins 
are presented in Figures 2 and 3. 
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cpm/mg protein (*1000) 
100 
gamma 
Figure 2 Incorporation of radioactivity in C3!!]-
NaBH4.treated WS proteins from clear 
lenses. 
cpm/mg protein (·1000) 
HM alpha 
senile cataract 
beta gamma 
diabetic cataract 
Figure 3 Incorporation of radioactivity in 
[^l-NaBH,-treated WS lens proteins of 
individuals with senile or diabetic 
cataract (± SD). 
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In all lenses radioactivity was highest in the HM-material, immediately followed by 
α-ciystallin. Incorporation of label in /3-crystallins was, roughly, half of that found in 
a-crystallin. Radioactivity was lowest in 7-crystallins, slightly below the values found 
for /J-crystallins. For example, the values for the 38 year old lens were: HM 3011 
cpm/mg, a-crystallin 2677 cpm/mg, 0-crystallins 1043 cpm/mg, 7-crystallins 778 
cpm/mg. As a function of age, there was a strong increase of early glycation 
products in the HM-material and α-crystallin, however slightly less prominent in a-
crystallin. During aging, there was only a slight increase in the content of early 
glycation products of ^-ciystallins (Figure 2). The incorporation of label in 7-
ciystallins was also almost constant as a function of time, showing slightly lower 
values compared with /}-ciystallins. The values for the different crystallin fractions 
obtained from senile and diabetic cataractous lenses followed the patterns described 
above. Again, incorporation of label was most prominent in the HM-material and a-
crystallin. Levels of radioactivity were clearly higher in lenses obtained from diabetic 
individuals compared with both, senile cataractous and clear lenses of similar age 
(Figure 3). 
Advanced glycation products were investigated by monitoring fluorescence 
(excitation/emission wavelengths 370/440 nm). In vitro glycation of crystallins 
generates fluorophores with these specific wavelenghts (Van Boekel and Hoenders, 
1991). Values were expressed as fluorescence per milligram protein (as determined 
by the BCA assay, Smith et al., 1985). The results are presented in Figures 4 and 5. 
With age, we observed a strong increase in specific fluorescence in all crystallin 
fractions. Fluorescence was highest in the HM material and decreased in the order 
HM > α-crystallin > ^-crystallins > 7-crystallins. Advanced glycation products were 
also studied in lenses from patients with senile or diabetic cataract. Senile 
cataractous lenses showed only slightly higher levels of fluorescence in comparison 
with clear lenses. However, fluorescence was significantly higher in lenses from 
individuals with diabetic cataract (Figure 5). The increase of fluorescence, 
compared with the lenses with senile cataract, were : HM 108 % , a-ciystallin 
109 %, 0-crystallins 83 % and 7-crystallins 54 % increase. 
6 6 
fluorescence (·1000) 
100 
HM alpha —*" beta gamma 
Figure 4 S p e c i f i c f l u o r e s c e n c e 
(excitation/emission wavelengths 
370/440 nm) of WS proteins from 
clear lenses . 
fluorescence («1000) 
senile cataract 
beta 
diabetic cataract 
Figure 5 S p e c i f i c f l u o r e s c e n c e 
(excitation/emission wavelengths 
370/440 nm) of WS lens proteins 
from individuals with sen i l e or 
diabetic cataract (± SD). 
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DISCUSSION 
Glycation of proteins is considered to be an age-dependent process. However, 
studies concerning glycation of crystallins do not show consistent results: some 
investigators report a clear increase of early glycation levels with age (Chio et al., 
1981; Garlick et al., 1984) while others find only minor differences between young 
and older material (Baynes et al., 1989; Lyons et al., 1990). We investigated not 
only WS protein fractions from lenses of different age, but also discriminated 
between different crystallin fractions. HM- and a-crystallin showed a clear increase 
in early glycation levels with age, while levels in β- and 7-ciystallins remained 
relatively constant (Figure 2). HM-crystallin consists for a considerable part of a-
crystallin. We therefore suggest a prominent role for α-crystallin when considering 
glycation of eye lens proteins. During experimental procedures, the proteins with a 
relatively high molecular weight show a tendency to aggregate and precipitate. When 
not handled carefully, protein samples easily loose HM- and α-crystallin, and become 
enriched in β- and Y-crystallins. Especially old and cataractous lenses are 
characterized by rapid loss of high-molecular water-soluble proteins. This could 
explain the slight increase in early glycation products in old material as observed by 
some investigators (Baynes et al., 1989). Levels of early and advanced glycation 
products were significantly elevated in lenses from diabetic patients, compared with 
clear and cataractous lenses obtained from individuals with comparable age (Figures 
2, 3, 4 and 5). Remarkably, early glycation products hardly increased in β- and 7-
crystallins during aging, while fluorescence increased more prominently (Figures 2 
and 3). Because early glycation products are only the first step in a long series of 
reactions, the reducible Amadori product and Schiff base can be considered as an 
indicator of the rate of glycation while the advanced glycation end products 
represent the final levels of glycation. This interpretation indicates that the glycation 
rate in β- and 7-crystallins remains constant as a function of age, whereas the 
glycation rate of α-crystallin (and eventually HM) speeds up during aging. The a-
crystallin molecule probably first undergoes, in course of time, conformational 
changes which make lysine residues more accessible for glycation. These changes 
could be initiated by early glycation or other age-dependent protein modification, 
resulting in changes in the tertiary structure of the molecule. Conformational 
changes are more relevant in molecules with a high molecular weight such as a-
crystallin. These findings are confirmed by in vitro glycation of crystallins with 
glucose, showing a rapid initial glycation of 7-crystallins. On the other hand, in vitro 
glycation of a-crystallin started slowly followed by a steep increase (Swamy and 
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Abraham, 1991). When investigating glycation of bovine a-crystallin subunits we 
found a preferential glycation of aA compared with aB chains (Van Boekel and 
Hoenders, accepted for publication). Remarkably, post-translational modifications (as 
shown for oxidation and racemization in a-crystallin) do not occur at random at all 
potential sites in the protein chain, but take place at preferential residues (Groenen 
et al., 1991; McDermott et al., 1991). These preferential sites are probably, because 
of their location and micro-environment, more susceptible for modification. The 
presence of highly glycation-sensitive residues could explain the preferential 
modification of aA subunits. Our investigations suggest a prominent role for a-
crystallin as far as glycation is concerned. Some investigators oppose to the role of 
glycation in the generation of diabetic cataract and propose a mechanism called the 
polyol pathway to explain the high frequency of cataract in diabetics (Kinoshita et 
al., 1962; Kinoshita et al, 1981). Indeed, the aldose reductase inhibitor sorbinil has 
shown to be effective in lowering non-tryptophan fluorescence and high-molecular-
weight protein formation in rat lenses (Nagaraj and Monnier, 1990). Others favor 
the influence of oxidative processes (including the generation of radicals) in 
combination with classic glycation to explain diabetic cataract (Wolff and Dean, 
1987). Reaction of crystallins with reducing sugars, intensified by other modifications, 
could easily lead to conformational changes, crosslinking and aggregation which have 
shown to be the initiating processes leading to cataract (Harding and Crabbe, 1984). 
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GLYCATION OF IMMUNOGLOBULINS IgG, IgA AND IgM 
IN PATIENTS WITH DIABETES MELLITUS 
SUMMARY 
Sera from diabetic patients and normal healthy individuals were used to investigate in 
vivo glycation of immunoglobulins. For in vitro studies we used IgG of patients with a 
monoclonal gammapathy (a monoclonal B-cell proliferation characterized by the 
production of homogeneous immunoglobulins) as a model. Reactivity of a number of 
sugars for these IgG's was investigated using isoelectric focusing and measuring HMF* 
(hydroxymethyl furfural) release after hydrolysis with oxalic acid. Immunoglobulins G 
were holated from sera of patients suffering from diabetes mellitus and from sera of 
normal individuals. Tlie IgG's from diabetes mellitus patients showed a higher degree of 
glycation in comparison with controls. A positive correlation with regard to the glycation 
degree of albumin and hemoglobin was found. Abo Immunoglobulins A and IgM 
isolated from sera of diabetic patients showed higher glycation levels compared with 
controls. 
Key words : glycation, diabetes, immunoglobulins, IgG, IgA, IgM, monoclonal 
gammapathy 
INTRODUCTION 
Glycation, or non-enzymatic glycosylation, is the condensation reaction between a 
reducing sugar and protein lysine residues. As experiments over the last 15 years 
reveal, glycation is a common protein modification in vivo (Krantz et al., 1986; 
Cerami et al., 1987; Van Boekei 1991). An important factor in the glycation levels 
* Abbreviations: HMF, hydroxymethyl furfural; Ig immunoglobulin; PBS, 
phosphate-buffered saline; TCA, trìchloro acetic acid; HPLC, high-pressure liquid 
chromatography; SDS-PAGE, sodium dodecyl sulphate - Polyacrylamide gel 
electrophoresis; HPGPC, high-pressure gel permeation chromatography; SD, standard 
deviation. 
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of a protein is its half-life in the body; long-lived proteins become eventually 
glycated to a higher extent. Diabetics and individuals suffering from galactosaemia 
are, because of their poorly controlled blood sugar levels, in a more severe way 
subjected to this process. The complications in these patients, such as cataract and 
atherosclerosis, resemble the symptoms seen during aging. Possibly, glycation is a 
fundamental mechanism by which these symptoms are induced in both, aging and 
diabetes. Proteins which only remain present in the body for short periods of time 
(such as serum proteins) are also subjected to glycation. In fact, glycation levels of 
albumin and hemoglobin are used as a parameter for the levels of glucose control 
in diabetics (Goldstein et al., 1982; Winocour et al., 1989). In glycation research, 
much attention has been paid to the modification of albumin and hemoglobin 
(Garlick and Mazer, 1984; Fluckiger, 1988; Yue et al., 1988). Little is known about 
the glycation of other serum proteins such as the immunoglobulins. In both, diabetes 
and aging, the immune system is less responsive to stimulation by mitogens (Zier et 
al., 1984). In this study we used IgG, isolated from patients with a monoclonal 
gammapathy, for in vitro experiments. We also isolated IgG, IgA and IgM from sera 
obtained from diabetic patients and healthy individuals and determined the glycation 
levels. 
MATERIALS AND METHODS 
Human sera 
Sera from patients suffering from monoclonal gammapathy were provided by the 
Elizabeth Hospital (Amersfoort, The Netherlands). Sera from normal healthy 
individuals were obtained from the Center of Blood Transfusion (Nijmegen, The 
Netherlands). One hundred sera were pooled and used for these experiments. Sera 
from diabetic patients were provided by the St Radboud Hospital (Nijmegen, The 
Netherlands). 
Isolation of albumin and immunoglobulins 
Albumin was isolated from sera by Sepharose-Blue C1-6B (Pharmacia) affinity 
chromatography. IgG and IgA were isolated by Protein-A-Sepharose CL 48 
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(Pharmacia) and Jacaline (Pierce) affinity chromatography, respectively. For the 
isolation of IgM a specific IgM antiserum (Nordic) was immobilized using CNBr-
activated Sepharose 4B (Pharmacia). 
Incubation of IgG with sugars 
Incubations of monoclonal IgG in sterile phosphate-buffered saline (PBS : 140 mM 
NaCl, 3 mM KCl, 8 mM КН
г
РО„ 1.5 mM Na2HP04 pH 7.4), containing 0.02% 
sodium azide and 100 mM glucose, glucose-6-phosphate, galactose, fructose or 
ribose, were performed at 3TC. A control sample was incubated simultaneously. 
Incubated samples were dialyzed against PBS and stored at -20oC until further use. 
Cie-reversed-phase chromatographic determination of HMF 
To 0.5 ml of a protein solution (10 mg/ml) 0.250 ml M oxalic acid was added and 
incubation was performed at 100°C for 4.5 hours. Then 0.250 ml 40% TCA was 
added and samples were centrifuged for 5 minutes in a Beekman Minifuge to 
precipitate the protein. Supernatants were analyzed on a Qj-reversed-phase column 
(Bondapack) using 5 mM Η,ΡΟ« as an eluent and detecting the absorbance at 280 
nm. For quantification of the HMF-release standard samples of HMF (Aldrich) 
were injected. 
SDS-polyacrylamide gel electrophoresis/isoelectric focusing 
SDS-PAGE was performed using 11% slab gels and 4% stacking gels. For 
isoelectric focusing aciylamide gels containing 12% glycerol were used. Ampholyte 
mixture: 2% pH 3.5-10 (LKB), 2% pH 6.5-9 (Pharmacia) and 2% pH 8-10.5 
(Pharmacia). Proteins were stained with Coomassie Brillant Blue R250. 
Determination of hemoglobin HbA! 
The amounts of HbAi were obtained using the Quick-sep fast Hb test system 
(Isolab, Inc.). 
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RESULTS 
For in vitro experiments, IgG's from patients suffering from a monoclonal 
gammapathy were used. Isoelectric focusing of these IgG's resulted in only 3 or 4 
major bands (Figure la). IgG from normal healthy individuals produces a broad 
smear which makes it difficult to interpret small shifts in pi. 
В 
Figure 1 Isoelectric focusing of IgG's, pH range 
3.5 - 10.5. 
a) IgG from normal healthy individuals 
and IgG obtained from a patient with a 
monoclonal gammapathy. 
b) Monoclonal, 1, 3 and 5 days of 
incubation (controls,glucose-6-phosphate, 
ribose). 
c) Monoclonal, 3, 6, 12 and 18 days of 
incubation with glucose. 
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Incubation with glucose-6-phosphate and ribose (and to a lesser extent fructose, not 
shown) were the most effective monosaccharides in glycating the IgG. After 3 to 5 
days all IgG bands had moved to the most acidic part of the isoelectric focusing gel 
(Figure lb). Glucose and galactose showed considerably lower reactivity , resulting 
in band shifts after 18 days (Figure 1c). 
We quantified early glycation products of Ig's by measuring HMF release following 
hydrolysis with oxalic acid. Determination of HMF release of the glucose-6-
phosphate-, galactose- and glucose-incubated samples showed a clear-cut increase in 
glycation with continuous incubation and reflected the reactivities as described 
above. SDS-PAGE of up to 7 days incubated samples showed no crosslinking of IgG 
(results not shown). When IgG samples were incubated up to 20 days with glucose-
6-phosphate or ribose, crosslinking did occur. Determination of HMF release in IgG 
from diabetic patients and normal healthy individuals revealed a much higher degree 
of glycation for the first ones. Values were 0.940 and 0.469 nmol HMF/mg IgG, 
respectively, for the diabetic and the control group (Figure 2). 
HMF release of IgG (nmol/mg) 
0.8 
0.6 -
0.4 
0.2 
Healthy individuals Diabetic patients 
Figure 2 HMF re lease from IgG obtained from 
d i abe t i c subjects and normal heal thy 
indiv iduals (± SD) . 
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Comparison of glycation levels of IgG versus albumin and IgG vs hemoglobin 
showed a positive correlation. Correlation coefficients were г = 0.781 and r = 0.691, 
respectively. IgG's of diabetic subjects were analyzed by SDS-PAGE and HPGPC, 
but showed no difference compared with controls. IgA was isolated from individual 
sera obtained from diabetes mellitus patients using Jacaline affinity chromatography 
(Pierce). As a control, we used a pool of 100 sera obtained from healthy individuals. 
When studying IgM glycation, sera from diabetic patients (8.0% <HbA,< 12.5%) 
were pooled. Levels of glycation were determined using the furfural HPLC assay. 
Results are shown in Figure 3. 
HMF release (nmol/mg) 
Healthy individuals Diabetic patients 
Figure 3 HMF release from IgA and IGM obtained 
from diabetic subjects and normal 
healthy individuals (± SD). 
Immunoglobulins IgA and IgM showed considerably higher levels in glycation 
compared with controls. Values were 0.805 nmol HMF/mg IgA and 1.010 nmol 
HMF/mg IgM for the diabetic group against 0.488 nmol HMF/mg IgA and 0.596 
nmol HMF/mg IgM for controls. 
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DISCUSSION 
For in vitro glycation studies of IgG we used samples derived from patients showing 
a monoclonal gammapathy. When analyzed on isoelectric focusing gels, these IgG 
samples showed only 3 or 4 major bands (Figure la). The most basic band 
represents the primary B-cell product, the more acidic bands unknown modification 
products of this protein. Incubation with sugars resulted in the formation of 
glycation products, as shown by change in pi and the release of HMF following mild 
hydrolysis. Glucose-6-phosphate and ribose (and to a lesser extent fructose) were the 
most reactive sugars probably due to their relatively high percentage of aldehyde 
form (Bunn and Higgins, 1981). In tissues of diabetic subjects levels of both, glucose 
and glucose-6-phosphate, are elevated (Srivastava, 1979; Gonzalez et al., 1980). It 
can be expected that both sugars contribute to the increase in hexose-glycation 
levels, found in our experiments. The importance of in vivo glycation by ribose has 
been demonstrated in experiments shown by Sell and Monnier (1989). Structure 
elucidation of a glycation crosslink led to the discovery of a pentose-mediated 
structure named pentosidine. This crosslink, composed of originally a pentose, lysine 
and arginine was present in a variety of human tissues including plasma proteins 
and red blood cells. 
Exact determination of glycation sites of Ig from normal individuals is virtually 
impossible, due to the heterogeneous character of the immunoglobulins. Some years 
ago, glycation of complement binding areas of the molecule was reported (Dolhofer 
et al., 1985). IgG of diabetic patients showed higher glycation levels compared with 
control IgG. A positive correlation with regard to the glycation of albumin and 
hemoglobin was found. The correlation with albumin was slightly better, thus 
reflecting the biological half-life values of these proteins. Although the high levels of 
early glycation products of IgG in diabetic patients are striking, no circulating 
crosslinked products could be found. 
The IgG's of diabetic patients showed no differences compared with controls when 
analyzed by SDS-PAGE and HPGPC. Possibly, the biological half-life of blood 
proteins is too short to form detectable amounts of circulating glycation-crosslinked 
products. However, there is a certain possibility of crosslinking with non-circulating 
protein as reported for myelin and glomerular tissue (Brownlee et al., 1986; Miller 
and Michael, 1976). 
Our results show elevated levels of glycation for IgM and IgA in patients with 
diabetes mellitus (Figure 3). For the isolation of IgA we used a new affinity 
chromatography column, containing the lectin jacaline from the seeds of Artocarpus 
81 
integrifolia (Roque-Barreira and Campos-Neto, 1985; Capon et al., 1990). Jacaline is 
a D-galactose binding lectin, suggesting binding of all immunoglobulin classes which 
contain this sugar. However, not only the oligosaccharide composition but also the 
sequence seems important: the presence of D-Gal as the terminal sugar in only IgA 
is probably the basis of the selective binding of IgA to jacalin (Roque-Barreira and 
Campos-Neto, 1985). Recent investigations suggest a binding of the IgAl but not 
the IgA2 subclass (Kondoh et al., 1986). However, serum IgA is predominantly 
present as IgAl, with an IgAl/IgA2 ratio of 89:11 (see Kerr et al., 1990 for a review 
article on IgA). Secretory IgA is mainly polymeric consisting of relatively large 
amounts of IgA2. The biological half-life of IgA is five times lower compared with 
IgG. The glycation levels of IgA can therefore be used as a short-time indicator of 
hyperglycaemia in patients with diabetes mellitus. IgG, IgM and IgA become clearly 
glycated to a higher extent in patients with diabetes mellitus. A recent study 
confirms the effect of reducing sugars on the structural properties of IgG, resulting 
in reduced in vitro Protein A binding and complement fixation (Dolhofer-Bliesener 
and Gerbitz, 1990). Since glycation has influence on structural aspects of proteins, 
these elevations could have consequences for the biological quality of the Ig's in 
vivo. 
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GLYCATION OF HUMAN SERUM ALBUMIN: INHIBITION 
BY DICLOFENAC 
SUMMARY 
Gfycation is a non-enzymatic modification of proteins by sugars, probably responsible for 
the initiation of complications in diabetes patients and aging individuaL·. Our in vitro 
experiments show an inhibition of sugar attachment in the presence of Diclofenac. The 
levels of advanced gfycation products, measured as specific fluorescent groups, were also 
lowered due to Diclofenac. Viese results were compared with inhibition by Aspirin, a 
known inhibitor of the gfycation process. Vie protection by Diclofenac is based on a 
non-covalent interaction of the drug with serum albumin. Viere is evidence that 
Diclofenac specifically blocks at least one of the major gfycation sites of human serum 
albumin. 
Key words : non-enzymatic glycosylation, glycation, diabetes mellitus, aging, human 
serum albumin, Diclofenac, Aspirin 
INTRODUCTION 
Glycation or non-enzymatic glycosylation is a well-studied post-translational protein 
modification. The reaction has a severe effect on the structure of proteins, changing 
their functional and biological properties. Because diabetic patients possess elevated 
blood sugar levels, they are more severely subjected to this process compared with 
normal, healthy individuals. Thus, glycation is thought to initiate the large number of 
complications seen in patients with diabetes (Monnier et al., 1990; Van Boekel, 
1991). Not only the sugar concentration but also the biological half-life of the 
protein is important in the level of protein modification; long-lived proteins are 
eventually glycated more extensively. This sheds light on the importance of glycation 
in aging individuals; protein modification and tissue damage during aging are 
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comparable with changes seen in diabetic patients (Monnier et al., 1990). Several 
attempts have been made to find suitable non-toxic glycation inhibitors. 
Aminoguanidine was introduced some years ago and showed ability to prevent 
diabetes-induced formation of advanced glycation products, including inhibition of 
protein crosslinking (Brownlee et al, 1986). Aminoguanidine protects the protein 
indirectly by decreasing the concentration of the highly reactive aldehyde form of 
the sugars (Lewis and Harding, 1990). Aspirin has shown to inhibit the glycation 
reaction in vitro and in vivo (Crompton et al., 1985; Rendell et al., 1986; Huby and 
Harding, 1988; Ajiboye and Harding, 1989) and is possibly effective in preventing 
sugar-induced cataract (Rao and Cotlier, 1985; Van Heyningen and Harding, 1986; 
Swamy and Abraham, 1989). Recently, the effect of other anti-inflammatory drugs 
such as Paracetamol and Ibuprofen have been investigated (Harding et al., 1989). 
We studied the influence of the anti-inflammatory drug Diclofenac (Figure 1) on 
glycation. 
Figure 1 Structure of Diclofenac 
(Voltaren) 
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This drug is usually administered in daily amounts of 100-200 mg (Small, 1989). 
Diclofenac is quickly and completely resorbed; plasmalevels are maximal after 2-3 
hours following intake. The drug is almost completely bound to plasmaproteins 
(Chamouard et al., 1985). We studied the effect of Diclofenac on the in vitro 
glycation of human serum albumin. We used glucose-6-phosphate because it is more 
reactive compared with glucose (Van Boekel and Hoenders, 1991). This allowed us 
to limit the incubation time of the samples. The direct sugar attachment as well as 
the development of fluorescent groups, typical for late glycation products, were 
investigated. 
MATERIALS AND METHODS 
Determination of early glycation products 
For determination of direct sugar attachment, 10 mg/ml HSA (human serum 
albumin, Hoechst-Behring) was incubated in phosphate buffer (137 mM NaCl, 2.7 
mM KCl, 8 mM NajHPO,, 1.4 mM ΚΗ,ΡΟ,, 1 mM EDTA, 0.05% NaN,, pH 7.3) 
with 5 mM glucose-6-phosphate (Merck). Furthermore, 5 /iCi "C-labeled glucose-6-
phosphate (uniformly-labeled, specific activity 295 mCi/mM sugar, Amersham) was 
added. 
To study the inhibitory effect, 1 or 5 mM Aspirin (Dispensary St Radboud Hospital, 
Nijmegen, The Netherlands) or Diclofenac (disodium salt, CIBA-GEIGY BV, 
Arnhem, The Netherlands) were added and incubation was performed at 37" С for 
1, 3 and 5 days. For time 0, samples were frozen immediately after addition of 
label. 
The amounts of protein-attached sugar were determined after TCA precipitation of 
200 μΐ incubated sample (triplicate) and precipitation on glassfiber niters (Schleicher 
and Schuil). The amounts of radioactivity were determined using a liquid scintillation 
counter (2200CA TRICARB, Packard). 
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Determination of advanced glycation endproducts 
For determination of advanced glycation products, 10 mg/ml HSA was incubated in 
phosphate buffer, pH 7.3 with 150 mM glucose-6-phosphate. To study the inhibitory 
effect, 20 mM Diclofenac was added and incubation was performed at 37' С for 14 
days. Samples were analyzed using an HPGPC (high-pressure gel permeation 
chromatography) system with combined Zorbax 450/250 colums (DuPont, both 28 
cm), preceded by a guard column (Biorad, PWH). We used a high-salt phosphate 
buffer (20 mM Na-phosphate, 100 mM NajSO,, 1 mM EDTA, pH 6.9) as an 
effluent. Determination was performed using a Hitachi 100-30 spectrophotometer 
and a Perkin-Elmer 204-A spectrofluorometer (excitation wavelength 370 nm; 
emission wavelength 440 nm). 
Pre-incubation of HSA 
In order to study the nature of Aspirin and Diclofenac interaction with albumin, 10 
mg/ml HSA was pre-incubated in a phosphate buffer (pH 7.3) with 5 and 20 mM 
Aspirin or Diclofenac for 5 days. 
After extensive dialysis against phosphate buffer (4 days at 4° С with multiple 
buffer changes), incubation with 5 mM glucose-6-phosphate containing radioactive 
label was performed as described above. After 5 days of incubation the amounts of 
incorporated radioactivity were counted following TCA precipitation. 
RESULTS AND DISCUSSION 
The reaction of glucose-6-phosphate with HSA and the effects of Aspirin and 
Diclofenac were investigated by incubation with radio-labeled sugar in the presence 
or absence of Aspirin and Diclofenac. Figure 2 shows the incorporation of sugar as 
a function of time. 
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Figure 2 Binding of glucose-6-phosphate 
to human serum albumin in the 
presence of 1 and 5 mM Diclofenac 
or 5 mM Aspirin: mean values ± 
standard deviation 
There is a clear increase of glucose-6-phosphate binding to albumin as incubation 
proceeds. Both Aspirin and Diclofenac significantly inhibit the incorporation of 
radioactivity compared with controls (S days of incubation; Students t-test, Ρ < 
0.05). The effect is most pronounced in the case of Diclofenac. 
In glycation research not the early glycation products, but advanced glycation 
endproducts (AGE's) are thought to play a role in the generation of so many 
complications seen in diabetes and aging individuals. To study the influence of 
Diclofenac on the generation of advanced glycation endproducts, we used 
fluorescence (excitation wavelength 370 nm; emission wavelength 440 nm) as a 
parameter. In vitro experiments show generation of fluorophores with these specific 
wavelengths following incubation of proteins with reducing sugars (Van Boekel and 
Hoenders, 1991). Incubation in the presence of Diclofenac resulted in a decrease in 
fluorescence as shown in Figure 3. 
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Figure 3 Specific fluorescence : 
HSA incubated alone, with 150 mM 
glucose-6-phosphate (G6P), with 
both 20 mM Diclofenac (Dici) and 
150 mM glucose-6-phosphate 
Thus, Diclofenac seems to be able to inhibit the generation of early as well as 
advanced glycation products. The protective property of Aspirin is based on the 
ability to acetylate amino groups of a protein, thus blocking the attachment of 
reducing sugars (Crompton et al., 1985; Rao and Collier, 1985; Rendell et al., 1986). 
Diclofenac has no acetyl groups to fulfil a similar reaction. 
The protective mechanism by which Diclofenac prevents glycation is unclear. To 
determine whether the interaction of Diclofenac with the protein is covalent or non-
covalent, we pre-incubated HSA with Diclofenac (and, as a control, with Aspirin) 
followed by dialysis and incubation with radio-labeled glucose-6-phosphate. The 
results are presented in Figure 4. 
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Figure 4 Binding of glucose-6-phosphate to HSA, 
pre-incubated with 5 and 20 mM Aspirin 
(Asp) or Diclofenac (Dici) : mean values 
± standard deviation 
Pre-incubation of HSA with Aspirin significantly decreased binding of glucose-6-
phosphate (Students t-test, Ρ < 0.05), obviously by acetylation as described earlier. 
Pre-incubation with 5 and 20 mM Diclofenac did not result in any protection for 
glucose-6-phosphate as seen during simultaneous incubation (Figure 4). Other 
authors report a rapid binding of Diclofenac to serum albumin (Terhaag et al., 
1985; Chan et al., 1987). In vivo. Diclofenac appeared to bind almost completely to 
plasma proteins (Chan et al., 1987). Kinetic studies revealed two specific binding 
sites of HSA for Diclofenac (Chamouard et al., 1985). These sites are formed by 
the HSA tertiary structure (Fehske et al., 1981), thus involving different parts of the 
primary structure. One Diclofenac binding site shows high affinity with a dominant 
role for His 146 and Lys 195. In the other binding site, which shows lower reactivity, 
Lys 199 plays a key role in the binding of Diclofenac (Fehske et al., 1981; 
Chamouard et al., 1985). This residue appeared to be one of the major glycation 
sites of HSA (Iberg and Fluckiger, 1986). 
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Over the last few years, the protective properties of several anti-inflammatory drugs 
against glycation have been demonstrated. Protection by Aspirin based on 
acetylation of amino groups has often been described (Rendell et al., 1986; Huby 
and Harding, 1988; Ajiboye and Harding, 1989). Recent experiments revealed the 
effect of Paracetamol (Harding et al., 1989) and Ibuprofen (Ajiboye and Harding, 
1989; Harding et al., 1989; Roberts and Harding, 1990; Raza and Harding, 1991). 
Many experiments were performed using lens proteins, the crystallins. Glycation is 
held responsible, at least partly, for the development of diabetic cataract, due to 
cross-linking of lens proteins resulting in the formation of high-molecular-weight 
material. Though glycation occurs easily on albumin as well as on crystallins, some 
authors warn against using albumin as a universal model for glycation research: the 
capacity of albumin to bind metal ions could initiate reactions not seen on other 
body proteins (Raza and Harding, 1991). Anyhow, the experiments concerning the 
glycation of HSA by glucose-6-phosphate and the inhibition by Diclofenac show 
convincing results. Compounds like Diclofenac and Ibuprofen appear to bind almost 
completely to albumin in vivo (Terhaag et al., 1985) which would make their actual 
concentration in the lens very low. Still, epidemiological studies suggest that 
Ibuprofen protects against cataract formation (Collier, 1981; Harding and Van 
Heyningen, 1988). Ibuprofen may act in an indirect way since it has been shown to 
lower blood glucose levels, thus reducing the risk of in vivo glycation (Chen and 
Robertson, 1979). 
Since serum albumin has a high affinity for Diclofenac, it would be interesting to 
investigate to which extent this affects its glycation in vivo. Possibly, the use of anti-
inflammatory drugs has an effect on the levels of glycated albumin currently used as 
a parameter for glycemia in diabetes patients. 
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SUMMARY 
Complications such as cataract, atherosclerosis, premature arteries and joint stiffness 
and nephropathy are common features in both, diabetics and aging individuals. 
These phenomena possibly have a shared origin. The glycation or Maillard reaction 
provides a suitable explanation for age-related changes on the molecular level which 
lead to serious dysfunction of tissues and organs (chapter 1). 
Chapter 2 describes the effects of in vitro glycation of calf lens crystallins. After 
incubation with a number of reducing sugars the crystallins were investigated for 
possible sugar-induced changes. Glucose-6-phosphate turned out to be a very 
reactive sugar, leading to protein modifications after just a few days of incubation at 
37" C. This incubation leads to an increase in molecular weight of all crystallin 
fractions and the generation of high-molecular-weight material. We also observed 
the occurrence of chromophores with specific wavelengths 335 and 370 nm. In vitro-
incubation resulted in a decrease in tryptophan fluorescence and a strong increase in 
specific non-tryptophan fluorescence with emission/excitation wavelengths 370/440 
nm. Remarkably, this fluorescence was not exclusively associated with the high-
molecular-weight protein but was present in all protein fractions. This finding 
supports the ideas of other investigators who suggest that crosslinking and 
fluorescent groups are not necessarily joint properties of advanced glycation 
products. 
We studied the in vivo glycation of crystallins isolated from prenatal bovine lenses, 
calf lenses and cow lenses (chapter 3). The glycation of bovine lens crystallins shows 
an increase with age, especially in the high-molecular-weight material (HM). This 
HM (which in the case of bovine lenses almost completely consists of a-crystallin) 
shows the highest glycation levels for early as well as advanced glycation products. 
These results suggest a prominent role for α-crystallin in the sugar-induced 
modification of crystallins. Remarkably, aA-subunits were glycated to a higher extent 
than aB-subunits. Possibly, the arrangement of the subunits in the a-crystallin 
molecule and the consequential susceptibility of lysine groups plays an important 
role in the glycation process. Future experiments should be focused on changes in 
the quaternary structure of α-crystallin due to glycation. A next step should be the 
determination of the favorite glycation sites on the aA- and aB-subunits. 
Chapter 4 deals with glycation of crystallins in human lenses. Because we were 
interested in the role of glycation in aging and diabetes, we used lenses from 
individuals showing senile and diabetic cataract. We also used clear lenses of 
different age. Levels of early glycation products in clear lenses were high in the 
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high-molecular-weight material (HM) and the α-crystallin fractions, compared with ß-
andY-crystallins. 
Upon aging, the content of early glycation products increases clearly in HM and a· 
crystallin, whereas levels in β- and 7-crystallins remain relatively constant. These 
findings indicate an increase in glycation rate upon aging, while the rate of glycation 
of β- and Ύ-crystallins remain relatively constant. Levels of early glycation products 
were clearly elevated in lenses from cataractous diabetics, compared with individuals 
with clear lenses and senile cataract. The glycation of the crystallin fractions follow 
the pattern as found in clear lenses, showing high glycation levels for HM and a-
crystallin. The content of advanced glycation products (measured as specific 
fluorophores with excitation / emission wavelengths 370/440 nm) increased 
dramatically with age and was two-fold higher in the diabetic subjects. The increase 
with age and diabetes was found in all crystallin fractions, and decreased in the 
order HM > a- > β- > 7-ciystallin. Our experiments underline the importance of 
glycation in age-related modifications of crystallins and the initiation of diabetic 
cataract. We suggest a prominent role in this process for α-crystallin. Very recent 
experiments have shown the presence of the pentose-induced crosslink called 
pentosidine in crystallins from cataractous lenses. This glycation crosslink was 
present in very high levels in α-crystallin compared with β· and T-crystallins. These 
experiments confirm our belief in the importance of sugar-induced modification of 
α-crystallin in the development of diabetic cataract. Further experiments should 
elucidate the role of pentoses and other compounds such as ascorbic acid which 
have shown to play a role in the glycation of crystallins. 
In chapters 5 and 6 some aspects of glycation of serum proteins are discussed. 
Though the modifications of albumin and hemoglobin are well investigated and used 
as a parameter for the glycaemic state of diabetics, not much is known about the 
glycation of immunoglobulins. We used IgG of patients with a monoclonal 
gammapathy (a monoclonal B-cell proliferation characterized by the production of 
homogeneous immunoglobulins) as a model. These experiments illustrate the 
extremely high reactivity of pentoses such as ribose. Recent experiments show the 
occurrence of the ribose-derived crosslink pentosidine in serum proteins in vivo. The 
in vivo glycation of IgG, IgA and IgM in diabetic patients and normal healthy 
individuals was investigated measuring HMF (hydroxymethyl furfural) release after 
hydrolysis with oxalic acid. Glycation of IgG showed a positive correlation with the 
glycation levels of albumin and hemoglobin. IgG, IgA and particularly IgM isolated 
from sera of diabetic patients showed higher glycation levels compared with controls. 
It is still unclear if the modification has an influence on the biological quality of the 
immunoglobulins. Further experiments should elucidate the consequences for the 
immune response following modification by reducing sugars. 
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Considering the high frequency of diabetes mellitus, many investigators have tried to 
find suitable non-toxic inhibitors of the Maillard reaction. Recent investigations 
involve the effect of aminoguanidine, aspirin and anti-inflammatory drugs such as 
paracetamol and ibuprofen. We studied the influence of diclofenac (chapter 6). This 
drug is able to inhibit glycation of human serum albumin in vitto. The levels of early 
as well as advanced glycation products were significantly lowered due to the 
presence of diclofenac. The protection of the drug is based on a non-covalent 
interaction with serum albumin. There is evidence that diclofenac specifically blocks 
sugar attachment: lysine residue 199, which is the major glycation site of albumin, 
plays a key role in the binding of diclofenac. 
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SAMENVATTING 
Er zijn vele hypothesen ontwikkeld die een mogelijke verklaring bieden voor de 
fundamentele veranderingen die in het lichaam optreden als gevolg van veroudering. 
Opvallend is dat symptomen van veroudering zoals staar, nefropathie, athérosclérose 
en verminderde elasticiteit van bindweefsel in vaatwanden en gewrichten al op 
relatief vroege leeftijd optreden bij patiënten met suikerziekte. Deze waarneming 
wekt de suggestie dat diabetes patiënten onderhevig zijn aan een versnelde 
veroudering. De verhoogde bloedsuikerconcentratie in deze patiënten en de als 
gevolg hiervan versnelde 'Versuikering" (de glycering- oftewel Maillard-reactie) van 
lichaamseiwitten speelt mogelijk een rol bij het ontstaan van de complicaties. 
Opvallend is bovendien dat verouderingsverschijnselen vooral optreden in weefsels 
die eiwitten bevatten die een relatief lange levensduur (lage "turn over") bezitten en 
dus alle kans bieden op ophoping van glyceringsproducten. Bovendien is gebleken 
dat voedselrestrictie bij proefdieren leidt tot lage bloedsuikerconcentraties, relatief 
weinig glycering van eiwitten en uiteindelijk een vertraging van 
verouderingsprocessen. Deze waarnemingen suggereren dat glycering een rol speelt 
bij zowel veroudering als bij de complicaties die optreden in diabetes patiënten 
(hoofdstuk 1). 
Hoofdstuk 2 beschrijft een modelstudie van in vitro glycering van ooglenseiwitten 
(crystallines) uit kalverlenzen. Na incubatie met een aantal reducerende suikers 
werden de monsters onderzocht op suiker-geinduceerde veranderingen. Incubatie 
met glucose-6-fosfaat bleek te resulteren in een toename in moleculair gewicht van 
alle crystalline-fracties en het ontstaan van hoog-moleculaire eiwitaggregaten. 
Bovendien ontstonden chromoforen met de specifieke absorptiegolflengten 335 en 
370 nm. In vitro incubatie met glucose-6-fosfaat had een daling in de tryptofaan-
fluorescentie en een sterke stijging van een specifieke non-tryptofaan fluorescentie 
met emissie/excitatie golflengten 370/440 nm tot gevolg. Deze fluorescentie was niet 
exclusief aanwezig in de hoog-moleculaire aggregaten, maar in alle ciystalline-
fracties. Deze waarneming ondersteunt de bevinding van andere onderzoekers dat 
crosslinking en fluorofore eigenschappen niet noodzakelijk gemeenschappelijke 
eigenschappen hoeven te zijn van late glyceringsproducten. 
We bestudeerden de in vivo glycering van crystallines uit lenzen van prenatale 
runderen, kalveren en koeien (hoofdstuk 3). De glycering van rundercrystallines laat 
een toename zien met de leeftijd, vooral in materiaal met een hoogmoleculair 
gewicht (HM). Dit HM (dat in het geval van runderen vrijwel volledig bestaat uit a-
crystalline) bevat het hoogste gehalte aan zowel vroege als late glyceringsproducten. 
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Deze resultaten suggereren een prominente rol voor a-ciystalline in suiker-
geinduceerde veranderingen van crystallines. Merkwaardig genoeg bleken de aA-
subunits hierbij sterker gemodificeerd te zijn dan de aB-subunits. Mogelijk speelt de 
rangschikking van de subunits in het a-crystalline-molecuul en de hier uit 
voortvloeiende toegankelijkheid van lysinegroepen voor suikers een rol in de 
glycering. Toekomstige experimenten zouden zich toe moeten spitsen op de 
veranderingen van de quaternaire structuur van α-crystalline door glycering. Een 
volgende stap zou kunnen zijn de bepaling van de exacte glycenngsplaatsen in de 
aA- en aB-subunits. 
Hoofdstuk 4 behandelt de glycering van crystallines uit humane lenzen. Omdat we 
geïnteresseerd waren in de rol van glycering bij veroudering en diabetes werden 
lenzen gebruikt afkomstig van individuen met een seniele of diabeteuze cataract. 
Ook werden heldere lenzen van verschillende leeftijden gebruikt. De hoeveelheden 
vroege glyceringsproducten in heldere lenzen waren hoog in de HM- en de a-
crystalline-fracties, vergeleken met β- en 7-ciystalline. De hoeveelheden vroege 
glyceringsproducten nemen als functie van de leeftijd duidelijk toe in HM en a-
crystalline, terwijl deze in β- en 7-crystalline relatief constant blijven. Deze 
bevindingen duiden op een toename in glyceringssnelheid in α-crystalline met de 
leeftijd, tegenover een constante reactiesnelheid in het geval van β- en 7-ciystalline. 
De hoeveelheden vroege glyceringsproducten waren duidelijk verhoogd in de lenzen 
van cataracteuze diabetici, vergeleken met seniele cataract en heldere lenzen. De 
glycering van de ciystalline-fracties was analoog aan de patronen gevonden in de 
heldere lenzen met de hoogste niveaus voor HM- en α-crystalline. De hoeveelheden 
late glyceringsproducten (gemeten als specifieke fluoroforen met excitatie / emissie 
golflengten 370 / 440 nm) namen dramatisch toe met de leeftijd en waren ongeveer 
een factor 2 hoger in diabeteuze personen vergeleken met de twee andere groepen. 
De toename met leeftijd en diabetes werd gevonden in alle ciystalline-fracties en 
nam af in de volgorde HM- > a- > β- > 7-crystalline. Onze experimenten 
onderstrepen het belang van glycering in leeftijd-gerelateerde modificaties van 
crystallines en de initiatie van diabeteuze cataract. We stellen een prominente rol 
van α-crystalline in dit proces voor. Zeer recente experimenten hebben het bestaan 
aangetoond van een pentose-geinduceerde crosslink (pentosidine) in crystallines uit 
cataracteuze lenzen. Deze glyceringscrosslink was sterk aanwezig in α-crystalline, 
vergeleken met β- en 7-crystallines. Deze bevindingen bevestigen ons vermoeden dat 
glycering van vooral α-crystalline een rol speelt in de ontwikkeling van diabeteuze 
cataract. Verdere experimenten zijn noodzakelijk om de rol van pentosen en andere 
stoffen zoals ascorbinezuur op te helderen die waarschijnlijk een rol spelen in de 
glycering van de crystallines. 
In de hoofdstukken 5 en 6 worden enkele aspecten van de glycering van 
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serumeiwitten besproken. De modificatie van albumine en hemoglobine door 
reducerende suikers is goed onderzocht en wordt in de kliniek routinematig 
gebruikt. Er is echter weinig bekend omtrent de glycering van Immunoglobulinen. 
Wij gebruikten IgG van patiënten met een monoclonale gammapathy (een 
monoclonale B-cel proliferatie gekarakteriseerd door de productie van homogene 
Immunoglobulinen) als een model voor in vitro experimenten. Deze experimenten 
demonstreren de extreem hoge reactiviteit van pentosen zoals ribose. Recente 
experimenten hebben al het bestaan in vivo aangetoond van de pentose-
geinduceerde crosslink pentosidine in serumeiwitten. De in vivo glycering van IgG, 
IgA en IgM bij diabetici en normale personen werd bestudeerd door bepaling van 
HMF (hydroxymethyl furfural) na hydrolyse van de eiwitten met oxaalzuur. De 
glycering van IgG liet een positieve correlatie zien t.o.v. de glycering van albumine 
en hemoglobine. IgG, IgA en vooral IgM afkomstig van sera van diabetici vertoonde 
hoge hoeveelheden glyceringsproducten, vergeleken met controles. Het is nog 
onduidelijk of de modificaties een invloed hebben op het functioneren van de 
Immunoglobulinen bij de immuunrespons. 
Er is veel werk verricht naar het vinden van geschikte non-toxische remmers van de 
Maillard-reactie. Recent onderzoek heeft de beschermende werking aangetoond van 
aspirine, paracetamol en Ibuprofen. Wij hebben de invloed van de pijnstiller 
diclofenac onderzocht (hoofdstuk 6). Deze stof is in staat de glycering van humaan 
serumalbumine in vitro te onderdrukken. De hoeveelheden vroege en late 
glyceringsproducten werden duidelijk lager door de aanwezigheid van diclofenac. De 
bescherming berust op een non-covalente interactie van de stof met albumine. Er 
zijn aanwijzingen dat diclofenac specifiek suikerbinding voorkomt: lysine residue 199, 
de voornaamste glycerings-bindingsplaats van albumine, speelt namelijk een 
sleutelrol in de binding van diclofenac. 
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